XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 28, 2021
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2019
Feb. 16, 2021
Dec. 31, 2020
Summary Of Significant Accounting Policies [Line Items]              
Continuation Advances     $ 34,000,000.0 $ 18,000,000.0      
Period in which company must repay continuation advances if change-of-control transaction is entered into with third party     2 years        
Equity or debt financing that must be raised in a single transaction     $ 100,000,000        
Period in which company must raise equity or debt financing in a single transaction     2 years        
Contingent repayment liability     $ 0       $ 0
Gain (loss) from Continuation Advances   $ (52,000,000) $ 34,000,000   $ 18,000,000.0    
Continuation Advances paid $ 52,000,000.0            
Fair value assets/liabilities transfer between levels   $ 0          
Sales Revenue, Net [Member] | Gene Company Limited [Member] | Customer Concentration Risk [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Concentration risk, percentage   12.00%          
Sales Revenue, Net [Member] | TOMY Digital Biology Co. [Member] | Customer Concentration Risk [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Concentration risk, percentage     11.00%        
Convertible Senior Notes [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Principal amount of notes $ 900,000,000            
Debt instrument, stated interest rate 1.50%         1.50%  
Maturity date   Feb. 15, 2028